Oncolytic Virus Competitive landscape report by DelveInsight

 Breaking News
  • No posts were found

Oncolytic Virus Competitive landscape report by DelveInsight

November 01
19:36 2022
Oncolytic Virus Competitive landscape report by DelveInsight
Oncolytic Virus pipeline
Oncolytic Virus pipeline constitutes 150+ key companies continuously working towards developing 175+ Oncolytic Virus treatment therapies, analyzes DelveInsight

The oncolytic viruses (OVs) are organisms able to identify, infect, and lyse different cells in the tumor environment, aiming to stabilize and decrease the tumor progression. They can present a natural tropism to the cancer cells or be oriented genetically to identify specific targets. Several OVs are being studied as a potential treatment for cancer in clinical trials. Moreover, the OVs are capable of contributing to the stimulation of the immune system against the tumor cells, influencing the development of an antitumor response.

 

DelveInsights, “Oncolytic Virus Competitive landscape, 2022,” report provides comprehensive insights about 150+ companies and Oncolytic Virus drugs in Oncolytic Virus inhibitors Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

To know more about the Oncolytic Virus Competitive landscape report, click here: Oncolytic Virus Competitive landscape

 

Key Takeaways from the Oncolytic Virus Competitive landscape report:

  • Leading Oncolytic Virus Companies working in the market are Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Virogin Biotech, Replimune, Viralytics, Oncolys Biopharma, Istari Oncology, Immvira Pharma, Seneca Therapeutics, Targovax, Lokon Pharma, ORCA Therapeutics, Beijing Syngen Tech, ViruCure, Tasly Pharmaceuticals, Turnstone Biologics, BioInvent, Transgene, Elicera Therapeutics and Others.
  • Key Oncolytic Virus therapies in various stages of development include CG0070, Pelareorep, OBP-301, TG6002, MED15395, Tasadenoturev and Others.
  • In May 2022, Calidi Therapeutics,had granted a new patent (No. US 11,285,194, Combination immunotherapy approach for treatment of cancer) by the US patent and Trademark Office (USPTO) related to its proprietary SuperNova (SNV) technology platform.

 

DelveInsight’s Oncolytic Virus Report covers around 175+ products under different phases of clinical development like

  • Assessment by Oncolytic Virus Product Type
  • Assessment by Stage and Product Type of Oncolytic Virus
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration of Oncolytic Virus
  • Assessment by Oncolytic Virus Molecule Type
  • Assessment by Stage and Molecule Type of Oncolytic Virus

 

Emerging Oncolytic Virus Drugs Under Different Phases of Clinical Development Include:

Some of the Oncolytic Virus therapies are VG161, CG0070 and Many Others.

 

Further Oncolytic Virus product details are provided in the report. Download the Oncolytic Virus Pipeline report to learn more about the emerging Oncolytic Virus therapies at: https://www.delveinsight.com/sample-request/oncolytic-virus-competitive-landscape

 

Key companies in the  Oncolytic Virus Therapeutics Market:

Some of the Oncolytic Virus Companies working in the market are Genelux Corporation, Candel Therapeutics, CG Oncology, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Virogin Biotech, Replimune, Viralytics, Oncolys Biopharma, Istari Oncology, Immvira Pharma, Seneca Therapeutics, Targovax, Lokon Pharma, ORCA Therapeutics, Beijing Syngen Tech, ViruCure, Tasly Pharmaceuticals, Turnstone Biologics, BioInvent, Transgene, Elicera Therapeutics and Others.

 

Request for Sample PDF Report to know in detail about the recent developments and advancements in Oncolytic Virus clinical trials: https://www.delveinsight.com/sample-request/oncolytic-virus-competitive-landscape

 

Table of Content (TOC)

1. Oncolytic Virus Pipeline Report Introduction

2. Oncolytic Virus Pipeline Report Executive Summary

3. Oncolytic Virus Pipeline: Overview

4. Analytical Perspective In-depth Commercial Assessment

5. Oncolytic Virus Clinical Trial Therapeutics

6. Oncolytic Virus Pipeline: Late Stage Products (Pre-registration)

7. Oncolytic Virus Pipeline: Late Stage Products (Phase III)

8. Oncolytic Virus Pipeline: Mid Stage Products (Phase II)

9. Oncolytic Virus Pipeline: Early Stage Products (Phase I)

10. Oncolytic Virus Pipeline Therapeutic Assessment

11. Inactive Products in the Oncolytic Virus Pipeline

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Key Oncolytic Virus Companies

14. Key Products in the Oncolytic Virus Pipeline

15. Unmet Needs

16. Oncolytic Virus Market Drivers and Barriers

17. Future Perspectives and Conclusion

18. Analyst Views

19. Appendix

 

Download Sample PDF Report to know more about @ Oncolytic Virus Drugs and Therapies

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end- to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/oncolytic-virus-competitive-landscape

Related Articles

Categories